Peijia Medical Ltd. 9996
HKEX · Hong Kong SAR China · Health Technology
HKD 4.62-0.19 (-4.05%)
Market open· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced its interim results for the six months ended June 30, 2026 (the "Reporting Period") on August 21, 2026. During the first half of 2026, the Group accelerated commercialization across its core businesses while delivering significant improvements in operational efficiency, profitability and cash generation.
As global markets grapple with inflation pressures and geopolitical uncertainties, Asian equities present a compelling narrative amidst these broader economic challenges. In this environment, identifying undervalued stocks can be particularly advantageous, as they may offer potential value relative to their intrinsic worth despite the prevailing market volatility.
As inflation pressures rise amid higher energy costs, Asian markets are navigating a complex landscape shaped by geopolitical uncertainties and fluctuating commodity prices. In this environment, identifying undervalued stocks can offer potential opportunities for investors seeking to capitalize on resilient sectors or companies with strong fundamentals.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.